DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07152756

Not yet recruiting

Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores

Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores: A Single-Center, Prospective, Observational Study

Lead sponsor

Fudan University

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

418

estimated

Study population

Perioperative / gastric aspiration risk

Key I/E criterion

•HbA1c ≤9%

Primary endpoint

•Gastric retention

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07152756
Org study ID2025K248

Timeline

Milestones

Study first posted2025-09-03actual
Last update posted2025-09-03actual
Study start2025-09-15estimated
Primary completion2028-09-15estimated
Study completion2028-09-15estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Perioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodProbability sample

Study population text

Participants undergoing sedated endoscopy who had discontinued semaglutide for one week prior to the procedure (with the last dose administered 8-14 days before EGD) were assigned to the exposure group, while those who had not used semaglutide were assigned to the non-exposure group.

Inclusion criteria

1. Subjects who have either: (i) been on long-term semaglutide therapy (≥4 weeks, any dosage) and discontinued use for one week prior to gastroscopy (with the last dose 8-14 days before the procedure), or(ii) never used semaglutide.

2. For patients with diabetes mellitus (DM), HbA1c < 9% to ensure adequate glycemic control.

3. Age ≥ 18 years, with no restriction on sex.

4. American Society of Anesthesiologists (ASA) physical status classification I-II.

5. Fasting for at least 8 hours and no water intake for at least 4 hours before gastroscopy.

6. Undergoing painless (sedated) endoscopy.

Exclusion criteria

1. History of hiatal hernia or any previous gastric surgery (including gastrectomy, Roux-en-Y gastric bypass, etc.).

2. Pregnancy.

3. Medically unfit for gastrointestinal endoscopy.

4. Deemed unsuitable for participation at the discretion of the investigators.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
2
Safety / tolerability / PK
1

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Rate of hypoxemia and aspiration events

Time frame:immediately after the esophagogastroduodenoscopy

event count, event

componentshypoxemia, aspiration event

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Rate of gastric retention

Time frame:immediately after the esophagogastroduodenoscopy

categorical status, event

Secondary/protocol endpoint

Gastric Mucosal Visibility Score

Time frame:immediately after the esophagogastroduodenoscopy

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.